Parkwood LLC Sells 11,076 Shares of AstraZeneca PLC $AZN

Key Points

• Parkwood LLC has reduced its holdings in AstraZeneca PLC by 9.4%, selling 11,076 shares and leaving it with 107,123 shares valued at approximately $7.87 million as of the latest SEC filing.
• AstraZeneca's recent earnings report revealed an EPS of $1.09, matching analysts' expectations, and a 16.1% increase in revenue year-over-year at $14.46 billion.
• The company will pay a semi-annual dividend of $0.505 per share, with a significant dividend yield and a payout ratio of 37.97% as disclosed in their recent reports.

Parkwood LLC lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 9.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 107,123 shares of the company's stock after selling 11,076 shares during the period. Parkwood LLC's holdings in AstraZeneca were worth $7,874,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Lindbrook Capital LLC grew its holdings in shares of AstraZeneca by 1.9% during the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company's stock valued at $557,000 after purchasing an additional 141 shares during the last quarter. Principal Securities Inc. grew its holdings in shares of AstraZeneca by 0.5% during the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after purchasing an additional 142 shares during the last quarter. Sage Mountain Advisors LLC grew its holdings in shares of AstraZeneca by 3.4% during the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock valued at $329,000 after purchasing an additional 147 shares during the last quarter. CoreCap Advisors LLC grew its holdings in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after purchasing an additional 155 shares during the last quarter. Finally, Evergreen Capital Management LLC boosted its position in AstraZeneca by 0.7% during the 1st quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company's stock valued at $1,743,000 after buying an additional 155 shares during the period. Institutional investors own 20.35% of the company's stock.

Wall Street Analyst Weigh In

Separately, Berenberg Bank set a $97.00 price objective on AstraZeneca in a report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $86.00.

AstraZeneca Trading Down 0.4%

Shares of NASDAQ:AZN traded down $0.34 on Tuesday, hitting $81.22. The company had a trading volume of 2,378,877 shares, compared to its average volume of 3,480,057. The firm's 50-day simple moving average is $75.33 and its two-hundred day simple moving average is $72.84. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $82.41. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $251.89 billion, a price-to-earnings ratio of 30.53, a P/E/G ratio of 1.50 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period last year, the company posted $1.24 EPS. Equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's dividend payout ratio (DPR) is currently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.